<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1002210508
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Herptrex
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VALACICLOVIR
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        381
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hetero Labs Limited Unit &#x2013; III" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hetero Labs Limited Unit – III
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2950]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J05AB11
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Valaciclovir hydrochloride monohydrate belongs to a group of medicines called antivirals. It works by killing or stopping the growth of viruses called herpes simplex (HSV), varicella zoster (VZV) and cytomegalovirus (CMV).</p><p>Valaciclovir hydrochloride monohydrate can be used to:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; treat shingles (in adults)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; treat HSV infections of the skin and genital herpes (in adults and adolescents over 12 years old). It is also used to help prevent these infections from returning.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; treat cold sores (in adults and adolescents over 12 years old).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; prevent infection with CMV after organ transplants (in adults and adolescents over 12 years old)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; treat and prevent HSV infections of the eye that continue to come back (in adults and adolescents over 12 years old)</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Valaciclovir hydrochloride monohydrate:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to valaciclovir hydrochloride monohydrate or aciclovir or any of the other ingredients of this medicine (listed in Section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Don&rsquo;t take Valaciclovir hydrochloride monohydrate if the above applies to you. If you are not sure, talk to your doctor or pharmacist before taking Valaciclovir hydrochloride monohydrate.</p><p>&nbsp;</p><p>Warnings and precautions</p><p><strong>Check with your doctor or pharmacist before taking Valaciclovir hydrochloride monohydrate if:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; you have kidney problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; you have liver problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; you are over 65 years of age</p><p>&middot;&nbsp;&nbsp;&nbsp; your immune system is weak</p><p>If you are not sure if the above apply to you, talk to your doctor or pharmacist before taking Valaciclovir hydrochloride monohydrate.</p><p><u>Prevent passing genital herpes on to others</u></p><p>If you are taking Valaciclovir hydrochloride monohydrate to treat or prevent genital herpes, or you have had genital herpes in the past, you should still practice safe sex, including the use of condoms. This is important to prevent you passing the infection on to others. You should not have sex if you have genital sores or blisters.</p><p>Other medicines and Valaciclovir hydrochloride monohydrate</p><p>Tell your doctor or pharmacist if you are taking or have recently taken any other medicines. This includes medicines obtained without a prescription, including herbal medicines<em>.</em></p><p>Tell your doctor or pharmacist if you are taking any other medicines that affect the kidneys. These include: aminoglycosides, organoplatinum compounds, iodinated contrast media, methotrexate, pentamidine, foscarnet, ciclosporin, tacrolimus, cimetidine and probenecid.</p><p>&nbsp;</p><p>Always tell your doctor or pharmacist about other medicines if you are taking Valaciclovir hydrochloride monohydrate for treatment of shingles or after having an organ transplant.</p><p>Pregnancy and breast-feeding</p><p>Valaciclovir hydrochloride monohydrate is not usually recommended for use during pregnancy. If you are pregnant, or think you could be, or if you are planning to become pregnant, don&rsquo;t take Valaciclovir hydrochloride monohydrate without checking with your doctor. Your doctor will weigh up the benefit to you against the risk to your baby of taking Valaciclovir hydrochloride monohydrate while you&#39;re pregnant or breastfeeding.</p><p>Driving or using machines</p><p>Valaciclovir hydrochloride monohydrate can cause side effects that affect your ability to drive.</p><p>&egrave; Don&rsquo;t drive or use machines unless you are sure you&rsquo;re not affected.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p>The dose that you should take will depend on why your doctor has prescribed Valaciclovir hydrochloride monohydrate for you. Your doctor will discuss this with you.</p><p><u>Treatment of shingles</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; The usual dose is 1000 mg (one 1000 mg tablet or two 500 mg tablets) three times a day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; You should take Valaciclovir hydrochloride monohydrate for seven days.</p><p><u>Treatment of cold sores</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; The usual dose is 2000 mg (two 1000 mg tablets or four 500 mg tablets) twice a day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; The second dose should be taken 12 hours (no sooner than 6 hours) after the first dose</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; You should take Valaciclovir hydrochloride monohydrate for one day (two doses) only.</p><p><u>Treatment of HSV infections of the skin and genital herpes</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; The usual dose is 500 mg (one 500 mg tablet or two 250 mg tablets) twice a day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; For the first infection you should take Valaciclovir hydrochloride monohydrate for five days or for up to ten days if your doctor tells you to. For recurrent infection the duration of treatment is normally 3-5 days.</p><p><u>Helping to prevent HSV infections from returning after you have had them</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; The usual dose is one 500 mg tablet once a day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Some people with frequent recurrences may benefit from taking one 250 mg tablet twice a day<strong>.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; You should take Valaciclovir hydrochloride monohydrate until your doctor tells you to stop.</p><p><strong><u>To stop you being infected with CMV (<em>Cytomegalovirus</em>)</u></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; The usual dose is 2000 mg (two 1000 mg tablets or four 500 mg tablets) four times a day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; You should take each dose about 6 hours apart.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; You will usually start taking Valaciclovir hydrochloride monohydrate as soon as possible after your surgery.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; You should take Valaciclovir hydrochloride monohydrate for around 90 days after your surgery, until your doctor tells you to stop.</p><p><u>Your doctor may adjust the dose of Valaciclovir hydrochloride monohydrate if:</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; you are over 65 years of age</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; you have a weak immune system</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; you have kidney problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Talk to your doctor before taking Valaciclovir hydrochloride monohydrate if any of the above apply.</p><p>Taking this medicine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Take this medicine by mouth.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Swallow the tablets whole with a drink of water.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Take Valaciclovir hydrochloride monohydrate at the same time each day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Take Valaciclovir hydrochloride monohydrate according to instructions from your doctor or pharmacist.</p><p>People over 65 years of age or with kidney problems</p><p><strong>It is very important while you are taking Valaciclovir hydrochloride monohydrate that you drink water regularly </strong>during the day. This will help to reduce side effects that can affect the kidney or nervous system. Your doctor will closely monitor you for signs of these. Nervous system side effects might include feeling confused or agitated, or feeling unusually sleepy or drowsy.</p><p>If you take more Valaciclovir hydrochloride monohydrate than you should</p><p>Valaciclovir hydrochloride monohydrate is not usually harmful, unless you take too much&nbsp; over several days. If you take too many tablets you may feel sick, vomit, get kidney problems, may be confused, agitated, feel less aware, see things that aren&rsquo;t there, or become unconscious. Talk to your</p><p>doctor or pharmacist if you take too much Valaciclovir hydrochloride monohydrate. Take the medicine pack with you.</p><p>If you forget to take Valaciclovir hydrochloride monohydrate</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If you forget to take Valaciclovir hydrochloride monohydrate, take it as soon as you remember. However, if it is nearly time for your next dose, skip the missed dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Don&rsquo;t take a double dose to make up for a forgotten dose.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may happen with this medicine:</p><p>Conditions you need to look out for</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; severe allergic reactions (<em>anaphylaxis</em>). These are rare in people taking Valaciclovir hydrochloride monohydrate. Rapid development of symptoms including:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; flushing, itchy skin rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the lips, face, neck and throat, causing difficulty in breathing (<em>angiodema</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; fall in blood pressure leading to collapse.</p><p>&egrave;If you have an allergic reaction, stop taking Valaciclovir hydrochloride monohydrate and see a doctor straight away.</p><p><strong>Very Common </strong>(may affect more than 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p><strong>Common </strong>(may affect up to 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; skin reaction after exposure to sunlight (<em>photosensitivity</em>).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; itching (<em>pruritus</em>)</p><p><strong>Uncommon </strong>(may affect up to 1 in 100 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; feeling confused</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; seeing or hearing things that aren&rsquo;t there (<em>hallucinations</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; feeling very drowsy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; tremors</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; feeling agitated</p><p>These nervous system side effects usually occur in people with kidney problems, the elderly or in organ transplant patients taking high doses of 8 grams or more of Valaciclovir hydrochloride monohydrate a day. They usually get better when Valaciclovir hydrochloride monohydrate is stopped or the dose reduced.</p><p><u>Other uncommon side effects:</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath (<em>dyspnoea</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; stomach discomfort</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; rash, sometimes itchy, hive-like rash (<em>urticaria</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; low back pain (kidney pain)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; blood in urine <em>(haematuria)</em></p><p><u>Uncommon side effects that may show up in blood tests:</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; reduction in the number of white blood cells (<em>leucopenia</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; reduction in the number of <em>blood platelets </em>which are cells that help blood to clot (<em>thrombocytopenia</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; increase in substances produced by the liver.</p><p><strong>Rare </strong>(may affect up to 1 in 1,000 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; unsteadiness when walking and lack of coordination (<em>ataxia</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; slow, slurred speech (<em>dysarthria</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; fits (convulsions)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; altered brain function (<em>encephalopathy</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; unconsciousness (<em>coma</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; confused or disturbed thoughts <em>(delirium)</em></p><p>These nervous system side effects usually occur in people with kidney problems, the elderly or in organ transplant patients taking high doses of 8 grams or more of Valaciclovir hydrochloride monohydrate a day. They usually get better when Valaciclovir hydrochloride monohydrate is stopped or the dose reduced.</p><p><u>Other rare side effects:</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Kidney problems where you pass little or no urine.</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.</p><p><strong><em>&nbsp;&bull; </em></strong><strong>Saudi Arabia<em>:</em></strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><em>o Other GCC States:</em></strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the carton. The expiry date (Exp.) refers to the last day of that month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Store below 30&deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Valaciclovir Tablets contains Valaciclovir Tablets 500 mg:</p><p>The active substance is Valaciclovir Hydrochloride Monohydrate.</p><p>&nbsp;</p><p>Each tablet contains 556 mg of Valaciclovir hydrochloride monohydrate equivalent to Valaciclovir hydrochloride monohydrate 500mg.</p><p>&nbsp;</p><p>The other ingredients are: Cellulose Microcrystalline, Crospovidone, Povidone, Purified water, Magnesium Stearate.</p><p>Coating composition: Hypromellose, Titanium dioxide, Polyethylene glycol/Macrogol, Polysorbate 80.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Valaciclovir Tablets looks like? Valaciclovir Tablets 500 mg:

White to off-white, film coated, Caplet shaped tablets, debossed with ‘V’ on one side and ‘500’ on the other side.

How supplied:

Valaciclovir Tablets are supplied in Blister pack. Valaciclovir Tablets 500 mg - 1 x 10’s Alu-PVC Blister Pack Valaciclovir Tablets 500 mg - 6 x 10’s Alu-PVC Blister Pack 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder and Manufacturer Saudi Amarox Industrial Company</p><p>Aljameah Street, Malaz quarter, Riyadh 11441 Saudi Arabia</p><p>Tel: +966 11 477 2215</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                December, 2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي فالاسيكلوفير هيدروكلوريد مونوهيدرات إلى مجموعة من الأدوية تسمى الأدوية المضادة للفيروسات. وهو يعمل عن طريق قتل أو إيقاف نمو الفيروسات التي تسمى الهربس البسيط (HSV)، الحماق النطاقية (VZV) والفيروس المضخم للخلايا (CMV).</p><p dir="RTL">يستخدم هيربتركس أقراص في الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج القوباء المنطقية (في البالغين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج التهابات فيروس الهربس البسيط في الجلد والقوباء التناسلية (لدى البالغين والمراهقين الذين تزيد أعمارهم عن 12 عامًا). كما أنه يستخدم للمساعدة في منع عودة هذه العدوى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج القروح الباردة (لدى البالغين والمراهقين الذين تزيد أعمارهم عن 12 عامًا).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; منع الإصابة بعدوى فيروس المضخم للخلايا CMV بعد زرع الأعضاء (في البالغين والمراهقين الذين تزيد أعمارهم عن 12 عامًا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج ومنع الإصابة بالتهابات فيروس الهربس البسيط في العين والتي قد تستمر في العودة (في البالغين والمراهقين الذين تزيد أعمارهم عن 12 عامًا)</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تقم باستعمال هيربتركس أقراص:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه فالاسيكلوفير هيدروكلوريد مونوهيدرات أو أسيكلوفير أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول هيربتركس أقراص إذا كان ما سبق ينطبق عليك. إذا لم تكن متأكدًا، فتحدث إلى طبيبك أو الصيدلي قبل تناول عقار هيربتركس أقراص.</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong><strong> </strong></p><p dir="RTL">استشر طبيبك أو الصيدلي قبل تناول هيربتركس أقراص:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشاكل في الكلى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشاكل في الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان عمرك يزيد عن 65 عامًا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من ضعف بالجهاز المناعي</p><p dir="RTL">إذا لم تكن متأكدًا مما إذا كان ما سبق ينطبق عليك، فتحدث إلى طبيبك أو الصيدلي قبل تناول هيربتركس أقراص.</p><p dir="RTL"><strong><u>منع نقل عدوى الهربس التناسلية إلى الآخرين</u></strong></p><p dir="RTL">إذا كنت تتناول هيربتركس أقراص لعلاج أو منع الهربس التناسلي، أو إذا كنت قد عانيت مسبقا من القوباء التناسلية، فلا يزال عليك ممارسة الجنس الآمن، بما في ذلك استخدام الواقي الذكري. هذا مهم لمنع نقل العدوى إلى الآخرين. يجب ألا تمارس الجنس إذا كان لديك تقرحات أو بثور.</p><p dir="RTL"><strong>تناول أدوية أخرى مع هيربتركس أقراص </strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت أي أدوية أخرى مؤخرًا. وهذا يشمل الأدوية التي تم الحصول عليها دون وصفة طبية، بما في ذلك الأدوية العشبية.</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أي أدوية أخرى تؤثر على الكلى. وتشمل هذه: أمينوجليكوزيدات، البلاتين العضوي، صبغات الأشعة والمعالجة باليود، الميثوتريكسيت، البنتاميدين، فوسكارنت، السيكلوسبورين، تاكروليماس، السيميتيدين والبروبينسيد.</p><p dir="RTL">أخبر طبيبك أو الصيدلي دائمًا عن الأدوية الأخرى إذا كنت تتناول هيربتركس أقراص لعلاج القوباء المنطقية أو بعد إجراء عملية زرع أعضاء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">عادةً لا يوصى باستخدام هيربتركس أقراص أثناء الحمل. إذا كنت حاملاً، أو تعتقد أنك يمكن أن تكوني حاملا، أو إذا كنت تخططين للحملً، فيجب عدم تتناول هيربتركس أقراص دون استشارة طبيبك. سيقوم الطبيب بموازنة الفائدة التي تعود عليك مقابل المخاطر التي قد يتعرض لها طفلك بسبب تناول هيربتركس أقراص أثناء الحمل أو الرضاعة الطبيعية.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">يمكن أن يسبب تناول هيربتركس أقراص آثار جانبية تؤثر على قدرتك على القيادة.</p><p dir="RTL">لا تقود أو تستخدم الآلات إلا إذا كنت متأكدًا من أنك لست متأثرًا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائمًا على تناول هذا الدواء تمامًا كما أخبرك الطبيب. يجب عليك استشارة طبيبك أو الصيدلي إذا كنت غير متأكد.</p><p dir="RTL">ستعتمد الجرعة التي يجب أن تتناولها على حالتك. طبيبك سوف يناقش هذا معك.</p><p dir="RTL"><strong><u>علاج القوباء المنطقية</u></strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة المعتادة هي 1000 ملغم (قرص 1000 ملغم أو قرصان 500 ملغم) ثلاث مرات في اليوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن تتناول هيربتركس أقراص لمدة سبعة أيام.</p><p dir="RTL"><strong><u>علاج القروح الباردة</u></strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة المعتادة هي 2000 ملغم (قرصان 1000 ملغم أو أربعة أقراص 500 ملغم) مرتين في اليوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن تتناول الجرعة الثانية خلال 12 ساعة (في موعد لا يتجاوز 6 ساعات) بعد الجرعة الأولى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن تتناول هيربتركس أقراص ليوم واحد (جرعتين) فقط.</p><p dir="RTL"><strong><u>علاج التهابات </u></strong><strong><u>HSV</u></strong><strong><u> في الجلد والقوباء التناسلية</u></strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة المعتادة هي 500 ملغم (قرص 500 ملغم أو قرصان 250 ملغم) مرتين في اليوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالنسبة للعدوى الأولى، يجب أن تتناول هيربتركس أقراص لمدة خمسة أيام أو لمدة تصل إلى عشرة أيام إذا أخبرك طبيبك بذلك. للعدوى المتكررة مدة العلاج عادة 3-5 أيام.</p><p dir="RTL"><strong><u>المساعدة في منع عدوى فيروس الهربس البسيط من العودة بعد الإصابة بها</u></strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة المعتادة هي قرص 500 ملغم مرة واحدة في اليوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يستفيد بعض الأشخاص الذين يعانون من تكرارات عودة العدوى من تناول قرص 250 ملغم مرتين في اليوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن تستمر في تناول هيربتركس أقراص حتى يخبرك طبيبك بالتوقف.</p><p dir="RTL"><strong><u>الوقاية من مرض </u></strong><strong><u>CMV</u></strong><strong><u> في حالة مرضى زرع الأعضاء (الفيروس المضخم للخلايا)</u></strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة المعتادة هي 2000 ملغم (قرصان 1000 ملغم أو أربعة أقراص 500 ملغم) أربع مرات في اليوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن تتناول كل جرعة خلال فترة حوالي 6 ساعات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستبدأ عادةً بتناول هيربتركس أقراص في أقرب وقت ممكن بعد الجراحة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن تتناول هيربتركس أقراص لمدة 90 يومًا تقريبًا بعد الجراحة، حتى يخبرك طبيبك بالتوقف.</p><p dir="RTL"><strong><u>قد يقوم طبيبك بضبط جرعة هيربتركس أقراص إذا:</u></strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان عمرك يزيد عن 65 عامًا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك ضعف في نظام المناعة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك مشاكل في الكلى.</p><p dir="RTL">تحدث إلى طبيبك قبل تناول هيربتركس أقراص إذا كان أي مما سبق ينطبق.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول هذا الدواء</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول هذا الدواء عن طريق الفم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابتلع الأقراص بالكامل مع شرب الماء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول هيربتركس أقراص في نفس الوقت كل يوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول هيربتركس أقراص وفقا لتعليمات الطبيب أو الصيدلي.</p><p dir="RTL"><strong>الأشخاص الذين تزيد أعمارهم عن 65 عامًا أو يعانون من مشاكل في الكلى</strong></p><p dir="RTL"><strong>من المهم جدًا أثناء تناولك هيربتركس أقراص أن تشرب الماء بانتظام خلال اليوم</strong>. هذا سوف يساعد على تقليل الآثار الجانبية التي يمكن أن تؤثر على الكلى أو الجهاز العصبي. سيقوم طبيبك بمراقبتك عن كثب بحثًا عن علامات على ذلك. قد تشمل الآثار الجانبية للجهاز العصبي الشعور بالارتباك أو الاستثارة، أو الشعور بالنعاس أو النعاس بشكل غير عادي.</p><p dir="RTL"><strong>الجرعة الزائدة من هيربتركس أقراص</strong></p><p dir="RTL">عادةً ما لا يكون هيربتركس أقراص ضارًا، إلا إذا تناولت جرعة زائدة ولعدة أيام. إذا كنت تناولت جرعة زائدة من هيربتركس أقراص، فقد تشعر بالغثيان والتقيؤ أو تعاني من مشاكل في الكلى أو قد تشعر بالارتباك أو الاستثارة والغضبً أو تشعر بأنك أقل وعياً أو ترى أشياء غير حقيقية أو تصبح غير واعي. تحدث إلى طبيبك أو الصيدلي إذا كنت تناولت جرعة زائدة من هيربتركس أقراص. خذ عبوة الدواء معك.</p><p dir="RTL"><strong>نسيان تناول أقراص من هيربتركس أقراص</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا نسيت تناول جرعة هيربتركس أقراص، تناولها حينما تتذكرها ومع ذلك، إذا حان وقت الجرعة التالية تقريبًا، تخطي الجرعة الفائتة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول جرعة مضاعفة لتعويض أقراص منسية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثاراً جانبية، على الرغم من عدم حدوثها للجميع.</p><p dir="RTL">الأعراض التي تحتاج إلى ملاحظتها</p><p dir="RTL">الحساسية الشديدة (الحساسية المفرطة). هذه نادرة لدى الأشخاص الذين يتناولون فالاسيكلوفير هيدروكلوريد مونوهيدرات. وتشمل أعراض التطور السريع للحالة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار، طفح جلدي حكة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الشفاه والوجه والعنق والحلق، مما يسبب صعوبة في التنفس (وذمة وعائية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في ضغط الدم مما يؤدي إلى السقوط.</p><p dir="RTL">&larr; إذا كان لديك رد فعل تحسسي، فتوقف عن تناول هيربتركس أقراص واستشر الطبيب على الفور.</p><p dir="RTL"><strong>شائع جدًا</strong> (قد يؤثر على أكثر من شخص من كل 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع الراس</p><p dir="RTL"><strong>شائع</strong> (قد يؤثر على شخص واحد من كل 10 أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالإعياء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل جلدي بعد التعرض لأشعة الشمس (حساسية للضوء).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة</p><p dir="RTL"><strong>غير شائع</strong> (قد يؤثر على ما يصل إلى شخص من كل 100 شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالارتباك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رؤية أو سماع أشياء غير موجودة (هلوسة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالنعاس بشدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الارتعاش</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالهياج</p><p dir="RTL">عادة ما تحدث هذه الآثار الجانبية للجهاز العصبي عند الأشخاص الذين يعانون من مشاكل في الكلى أو كبار السن أو لمرضى زراعة الأعضاء الذين يتناولون جرعات عالية من 8 غرامات أو أكثر من هيدروكلوريد فالاسيكلوفير كل يوم. عادة ما تتحسن عندما يتم إيقاف تناول هيربتركس أقراص أو تخفيض الجرعة.</p><p dir="RTL"><strong><u>آثار جانبية غير شائعة أخرى:</u></strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بعدم الراحة في المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، وأحيانًا حكة، مثل (الشرى)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام أسفل الظهر (آلام الكلى)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور للدم في البول (البول الدموي)</p><p dir="RTL"><strong><u>الآثار الجانبية غير الشائعة والتي قد تظهر في اختبارات الدم:</u></strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم البيضاء (قلة الكريات البيض)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد الصفائح الدموية التي تساعد على تجلط الدم (قلة الصفيحات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة المواد التي ينتجها الكبد.</p><p dir="RTL"><strong>نادر</strong> (قد يؤثر على شخص واحد من كل 1000 شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم الثبات عند المشي وعدم التنسيق (ترنح)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكلام البطيء والمغمور (خلل الحركة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات (التشنجات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير وظائف المخ (اعتلال الدماغ)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوعي (غيبوبة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأفكار المشوشة أو المضطربة (الهذيان)</p><p dir="RTL">عادة ما تحدث هذه الآثار الجانبية للجهاز العصبي عند الأشخاص الذين يعانون من مشاكل في الكلى أو كبار السن أو في مرضى زراعة الأعضاء الذين يتناولون جرعات عالية من 8 غرامات أو أكثر من هيدروكلوريد فالاسيكلوفير كل يوم. عادة ما تتحسن عندما يتم إيقاف تناول هيربتركس أقراص أو تخفيض الجرعة.</p><p dir="RTL"><u>آثار جانبية أخرى نادرة:</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الكلى حيث تمرر كمية قليلة من البول أو عدم مرور&nbsp;البول.</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية: </strong></p><p dir="RTL">إذا زادت حدة أي من هذه الأعراض الجانبية، أو لاحظت ظهور أعراض جانبية غير ما تم ذكره في هذه النشرة، يرجى إبلاغ الطبيب المعالج أو الصيدلي. وهذا يشمل أي آثار جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضا الإبلاغ عن الآثار الجانبية مباشرة (انظر التفاصيل أدناه). بالإبلاغ عن الآثار الجانبية يمكنك المساعدة في توفير مزيد من المعلومات حول أمان هذا الدواء.</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p dir="RTL"><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span dir=LTR></span><span
  dir=LTR></span><span dir=LTR><span dir=LTR></span><span dir=LTR></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span></span><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المركز الوطني للتيقظ والسلامة الدوائية</strong></p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; فاكس 7662-205-1-966+</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الاتصال على المركز الوطني للتيقظ والسلامة الدوائية +966-11-2038222 ، تحويلة: 2317-2356-2353-2354-2334-2340</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الهاتف المجاني: 8002490000</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني : npc .drug@sfda .gov .sa</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: www .sfda .gov .sa/npc</p></td></tr></tbody></table><!--[if mso & !supportInlineShapes & supportFields]><span
  dir=LTR><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:453.6pt;
   height:90.7pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span></span><![endif]--><p>&nbsp;</p><p dir="RTL"><strong>دول مجلس التعاون الخليجي الأخرى:</strong></p><p dir="RTL">&nbsp; &nbsp;يرجى الاتصال بالسلطة الصحية المختصة .</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ بعيدا عن متناول أيدي الأطفال أو على مرأى منهم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هيربتركس أقراص بعد انتهاء تاريخ الصلاحية المذكور على العبوة الخارجية. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في الشهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينبغي أن يتم التخلص من الأدوية في مياه الصرف الصحي أو عن طريق النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. هذه التدابير تساعد في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي فالاسيكلوفير هيدروكلوريد.</p><p dir="RTL">يحتوي كل قرص على 556 ملغم من فالاسيكلوفير مونوهيدرات هيدروكلوريد ما يعادل 500 ملغم فالاسيكلوفير.</p><p dir="RTL"><strong>الصواغات الأخرى هي</strong>: السليلوز دقيق التبلور، كروسبوفيدون، بوفيدون، ستيرات الماغنيسيوم، المياه النقية.</p><p dir="RTL"><strong>الصواغات الأخرى لطبقة الكسوة هي</strong>: هيبروميلوز، ثاني أكسيد التيتانيوم، بولي إيثيلين جليكول / ماكروجول، بولي سوربات 80.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هو شكل هيربتركس أقراص ومحتويات العلبة؟</strong></p><p dir="RTL"><strong>هيربتركس أقراص 500 ملغم</strong></p><p dir="RTL">أقراص على شكل كبسولة ذات لون الأبيض القاتم إلى الأبيض، والأقراص مغلفة بطبقة رقيقة ومدموغة بحرف &quot;V&quot; من جانب و &quot;500&quot; على الجانب الآخر.</p><p dir="RTL"><strong>توافر هيربتركس أقراص:</strong></p><p dir="RTL">يتوافر هيربتركس أقراص في عبوات حاوية.</p><p dir="RTL">تحتوي عبوة هيربتركس أقراص 500 ملغم على 10 و60 قرص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>صاحب حق التسويق:</strong></p><p dir="RTL"><strong>شركة أماروكس السعودية للصناعة</strong></p><p dir="RTL">شارع الجامعة &ndash; الملز &ndash; الرياض 11441</p><p dir="RTL">المملكة العربية السعودية.</p><p dir="RTL">تليفون: + 966 114772215</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            فبراير 2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Valaciclovir Tablets 500mg  
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets 500mg: 
Each tablet contains valaciclovir hydrochloride monohydrate equivalent to 500 mg valaciclovir

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Valaciclovir Tablets 500mg:  
White to off-white, film coated, caplet shaped tablets, debossed with ‘V’ on one side and ‘500’ on the other side. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Therapeutic indications</p><p>valaciclovir hydrochloride monohydrate is indicated for the treatment of herpes zoster (shingles) and ophthalmic zoster in immunocompetent adults (see sections 4.4).</p><p>valaciclovir hydrochloride monohydrate is indicated for the treatment of herpes zoster in adult patients with mild or moderate immunosuppression (see section 4.4). <u>Herpes simplex virus (HSV) infections</u> valaciclovir hydrochloride monohydrate is indicated</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; for the treatment and suppression of HSV infections of the skin and mucous membranes including:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treatment of first-episode of genital herpes in immunocompetent adults and adolescents and in immunocompromised adults.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treatment of recurrences of genital herpes in immunocompetent adults and adolescents, and in immunocompromised adults.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; suppression of recurrent genital herpes in immunocompetent adults and adolescents and in immunocompromised adults.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Treatment and suppression of recurrent ocular HSV infections in immunocompetent adults and adolescents and in immunocompromised adults (see section 4.4).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Clinical studies have not been conducted in HSV-infected patients immunocompromised for other causes than HIV-infection (see section 5.1).</p><p><u>Cytomegalovirus (CMV) infections:</u></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Valaciclovir hydrochloride monohydrate is indicated for the prophylaxis of CMV infection and disease following solid organ transplantation in adults and adolescents (see section 4.4)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Varicella zoster virus (VZV) infections &ndash; herpes zoster and ophthalmic zoster</u></p><p>Patients should be advised to start treatment as soon as possible after a diagnosis of herpes zoster. There are no data on treatment started more than 72 hours after onset of the zoster rash.</p><p>Immunocompetent Adults</p><p>The dose in immunocompetent patients is 1000 mg three times daily for seven days (3000 mg total daily dose). This dose should be reduced according to creatinine clearance (see Renal impairment below).</p><p>Immunocompromised Adults</p><p>The dose in immunocompromised patients is 1000 mg three times daily for at least seven days (3000 mg total daily dose) and for 2 days following crusting of lesions. This dose should be reduced according to creatinine clearance (see Renal impairment below).</p><p>In immunocompromised patients, antiviral treatment is suggested for patients presenting within one week of vesicle formation or at any time before full crusting of lesions.</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_17974" o:spid="_x0000_i1026" type="#_x0000_t75"
 style='width:431.25pt;height:32.25pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="575" height="43" alt="" vspace="0" hspace="0" border="0" style="width:575px;height:43px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /></p><p>The dose is 500 mg of Valaciclovir hydrochloride monohydrate to be taken twice daily (1000 mg total daily dose). This dose should be reduced according to creatinine clearance (see Renal impairment below).</p><p>For recurrent episodes, treatment should be for three to five days. For initial episodes, which can be more severe, treatment may have to be extended to ten days. Dosing should begin as early as possible. For recurrent episodes of herpes simplex, this should ideally be during the prodromal period or immediately upon appearance of the first signs or symptoms. Valaciclovir hydrochloride monohydrate can prevent lesion development when taken at the first signs and symptoms of an HSV recurrence.</p><p>Herpes labialis</p><p>For herpes labialis (cold sores), valaciclovir hydrochloride monohydrate 2000 mg twice daily for one day is effective treatment in adults and adolescents. The second dose should be taken about 12 h (no sooner than 6 h) after the first dose. This dose should be reduced according to creatinine clearance (see Renal impairment below). When using this dosing regimen, treatment should not exceed one day, since this has been shown not to provide additional clinical benefit. Therapy should be initiated at the earliest symptom of a cold sore (e.g. tingling, itching or burning).</p><p>Immunocompromised Adults</p><p>For the treatment of HSV in immunocompromised adults, the dosage is 1000 mg twice daily for at least 5 days, following assessment of the severity of the clinical condition and immunological status of the patient. For initial episodes, which can be more severe, treatment may have to be extended to ten days. Dosing should begin as early as possible. This dose should be reduced according to creatinine clearance (see Renal impairment below). For maximum clinical benefit, the treatment should be started within 48 hours. A strict monitoring of the evolution of lesions is advised.&nbsp;</p><p><u>Suppression of recurrences of herpes simplex virus (HSV) infections in adults and</u></p><p><!--[if gte vml 1]><v:shape
 id="Picture_x0020_17975" o:spid="_x0000_i1025" type="#_x0000_t75" style='width:265.5pt;
 height:32.25pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
  o:title=""/>
</v:shape><![endif]--><img width="354" height="43" alt="" vspace="0" hspace="0" border="0" style="width:354px;height:43px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /></p><p>The dose is 500 mg of Valaciclovir hydrochloride monohydrate to be taken once daily. Some patients with very frequent recurrences (&ge; 10/year in absence of therapy) may gain additional benefit from the daily dose of 500 mg being taken as a divided dose (250 mg twice daily). This dose should be reduced according to creatinine clearance (see Renal impairment below).Treatment should be re-evaluated after 6 to 12 months of therapy.</p><p>Immunocompromised Adults</p><p>The dose is 500 mg of Valaciclovir hydrochloride monohydrate twice daily. This dose should be reduced according to creatinine clearance (see Renal impairment below). Treatment should be re-evaluated after 6 to 12 months of therapy.</p><p><u>Prophylaxis of cytomegalovirus (CMV) infection and disease in adults and adolescents (&ge;12</u> <u>years)</u></p><p>The dosage of Valaciclovir hydrochloride monohydrate is 2000 mg four times a day, to be initiated as early as possible post-transplant. This dose should be reduced according to creatinine clearance (see Renal impairment below).</p><p>The duration of treatment will usually be 90 days, but may need to be extended in high-risk patients.</p><p>Special populations</p><p>Children</p><p>The efficacy of Valaciclovir hydrochloride monohydrate in children below the age of 12 years has not been evaluated.</p><p>Elderly</p><p>The possibility of renal impairment in the elderly must be considered and the dose should be adjusted accordingly (see Renal impairment below). Adequate hydration should be maintained.</p><p>Renal impairment</p><p>Caution is advised when administering Valaciclovir hydrochloride monohydrate to patients with impaired renal function. Adequate hydration should be maintained. The dose of Valaciclovir hydrochloride monohydrate should be reduced in patients with impaired renal function as shown in Table 1 below.</p><p>In patients on intermittent haemodialysis, the Valaciclovir hydrochloride monohydrate dose should be administered after the haemodialysis has been performed. The creatinine clearance should be monitored frequently, especially during periods when renal function is changing rapidly e.g. immediately after renal transplantation or engraftment. The Valaciclovir hydrochloride monohydrate dosage should be adjusted accordingly.</p><p>Hepatic impairment</p><p>Studies with a 1000 mg dose of valaciclovir hydrochloride monohydrate in adult patients show that dose modification is not required in patients with mild or moderate cirrhosis (hepatic synthetic function maintained). Pharmacokinetic data in adult patients with advanced cirrhosis (impaired hepatic synthetic function and evidence of portal-systemic shunting) do not indicate the need for dose adjustment; however, clinical experience is limited. For higher doses (4000 mg or more per day), see section 4.4.</p><p>Table 1: DOSAGE ADJUSTMENT FOR RENAL IMPAIRMENT</p><table border="0" cellspacing="0" cellpadding="0" style="width:638px"><tbody><tr><td style="vertical-align:top"><p><strong>Therapeutic Indication</strong></p></td><td style="vertical-align:top"><p><strong>Creatinine Clearance </strong></p><p><strong>(mL/min)</strong></p></td><td style="vertical-align:top"><p><strong>Valaciclovir Dosage<sup>a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Varicella-Zoster Virus (VZV)</p><p>Infections</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Treatment of herpes zoster</p><p>(shingles) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in immunocompetent and</p><p>immunocompromised adults</p></td><td style="vertical-align:top"><p>&ge; 50</p><p>30 to 49</p><p>10 to 29</p><p>10</p></td><td style="vertical-align:top"><p>1000 mg three times daily</p><p>1000 mg twice daily</p><p>1000 mg once daily</p><p>500 mg once daily</p></td></tr><tr><td style="vertical-align:top"><p>Herpes Simplex Virus (HSV)</p><p>Infections</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Treatment of HSV infections</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>- immunocompetent adults and adolescents</p></td><td style="vertical-align:top"><p>&ge; 30</p><p>&lt; 30</p></td><td style="vertical-align:top"><p>500 mg twice daily</p><p>500 mg once daily</p></td></tr><tr><td style="vertical-align:top"><p>- immunocompromised adults</p></td><td style="vertical-align:top"><p>&ge; 30</p><p>&lt; 30</p></td><td style="vertical-align:top"><p>1000 mg twice daily</p><p>1000 mg once daily</p></td></tr><tr><td style="vertical-align:top"><p>Treatment of herpes labialis</p><p>(cold &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sores) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in</p><p>immunocompetent adults and Adolescents (alternative 1-day regimen)</p></td><td style="vertical-align:top"><p>&ge;50</p><p>30 to 49</p><p>10 to 29</p><p>&lt;10</p></td><td style="vertical-align:top"><p>2000mg twice in one day</p><p>1000 mg twice in one day</p><p>500 mg twice in one day</p><p>500 mg single dose</p></td></tr><tr><td style="vertical-align:top"><p>Suppression &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; HSV</p><p>infections</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>immunocompetent adults and adolescents</p></td><td style="vertical-align:top"><p>&ge; 30</p><p>&lt; 30</p></td><td style="vertical-align:top"><p>500 mg once daily<sup>b</sup></p><p>250 mg once daily</p></td></tr><tr><td style="vertical-align:top"><p>immunocompromised adults</p></td><td style="vertical-align:top"><p>&ge; 30</p><p>&lt; 30</p></td><td style="vertical-align:top"><p>500 mg twice daily</p><p>500 mg once daily</p></td></tr><tr><td style="vertical-align:top"><p>Cytomegalovirus &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (CMV)</p><p>Infections</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>CMV prophylaxis in solid organ transplant recipients in adults and adolescents</p></td><td style="vertical-align:top"><p>&ge;75</p><p>50 to &lt;75</p><p>25 to &lt;50</p><p>10 to &lt;25</p><p>&lt;10 or on dialysis</p></td><td style="vertical-align:top"><p>2000 mg four times daily</p><p>1500 mg four times daily</p><p>1500 mg three times daily</p><p>1500 mg twice daily</p><p>1500mg once daily</p></td></tr></tbody></table><p>&nbsp;</p><p><sup>a</sup>For patients on intermittent haemodialysis, the dose should be given after dialysis on dialysis days.<sup> </sup></p><p><sup>b</sup>For HSV suppression in immunocompetent subjects with a history of &ge;10 recurrences/year, better results may be obtained with 250 mg twice daily.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to valaciclovir hydrochloride monohydrate or aciclovir or any of the excipients listed in section 6.1. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hydration status</p><p>Care should be taken to ensure adequate fluid intake in patients who are at risk of dehydration, particularly the elderly.</p><p>Use in patients with renal impairment and in elderly patients</p><p>Aciclovir is eliminated by renal clearance, therefore the dose of valaciclovir hydrochloride monohydrate must be reduced in patients with renal impairment (see section 4.2). Elderly patients are likely to have reduced renal function and therefore the need for dose reduction must be considered in this group of patients. Both elderly patients and patients with renal impairment are at increased risk of developing neurological side-effects and should be closely monitored for evidence of these effects. In the reported cases, these reactions were generally reversible on discontinuation of treatment (see section 4.8).</p><p>Use of higher doses of valaciclovir hydrochloride monohydrate in hepatic impairment and liver transplantation</p><p>There are no data available on the use of higher doses of valaciclovir hydrochloride monohydrate (4000 mg or more per day) in patients with liver disease. Specific studies of valaciclovir hydrochloride monohydrate have not been conducted in liver transplantation, and hence caution should be exercised when administering daily doses greater than 4000 mg to these patients.</p><p>Use for zoster treatment</p><p>Clinical response should be closely monitored, particularly in immunocompromised patients. Consideration should be given to intravenous antiviral therapy when response to oral therapy is considered insufficient.</p><p>Patients with complicated herpes zoster, i.e. those with visceral involvement, disseminated zoster, motor neuropathies, encephalitis and cerebrovascular complications should be treated with intravenous antiviral therapy.</p><p>Moreover, immunocompromised patients with ophthalmic zoster or those with a high risk for disease dissemination and visceral organ involvement should be treated with intravenous antiviral therapy.</p><p>Transmission of genital herpes</p><p>Patients should be advised to avoid intercourse when symptoms are present even if treatment with an antiviral has been initiated. During suppressive treatment with antiviral agents, the frequency of viral shedding is significantly reduced. However, the risk of transmission is still possible. Therefore, in addition to therapy with valaciclovir hydrochloride monohydrate, it is recommended that patients use safer sex practices.</p><p>Use in ocular HSV infections</p><p>Clinical response should be closely monitored in these patients. Consideration should be given to intravenous antiviral therapy when response to oral therapy is unlikely to be sufficient.</p><p>Use in CMV infections</p><p>Data on the efficacy of valaciclovir hydrochloride monohydrate from transplant patients (~200) at high risk of CMV disease (e.g. donor CMV-positive/recipient CMV negative or use of antithymocyte globulin induction therapy) indicate that valaciclovir hydrochloride monohydrate should only be used in these patients when safety concerns preclude the use of valganciclovir or ganciclovir.</p><p>High dose valaciclovir hydrochloride monohydrate as required for CMV prophylaxis may result in more frequent adverse events, including CNS abnormalities, than observed with lower doses administered for other indications (see section 4.8). Patients should be closely monitored for changes in renal function, and doses adjusted accordingly (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The combination of valaciclovir hydrochloride monohydrate with nephrotoxic medicinal products should be made with caution, especially in subjects with impaired renal function, and warrants regular monitoring of renal function. This applies to concomitant administration with aminoglycosides, organoplatinum compounds, iodinated contrast media, methotrexate, pentamidine, foscarnet, ciclosporin, and tacrolimus.</p><p>Aciclovir is eliminated primarily unchanged in the urine via active renal tubular secretion. Following 1000 mg valaciclovir hydrochloride monohydrate, cimetidine and probenecid reduce aciclovir renal clearance and increase the AUC of aciclovir by about 25% and 45%, respectively, by inhibition of the active renal secretion of aciclovir. Cimetidine and probenecid taken together with valaciclovir hydrochloride monohydrate increased aciclovir AUC by about 65%. Other medicinal products (including e.g. tenofovir) administered concurrently that compete with or inhibit active tubular secretion may increase aciclovir concentrations by this mechanism. Similarly, valaciclovir hydrochloride monohydrate administration may increase plasma concentrations of the concurrently administered substance.</p><p>In patients receiving higher aciclovir exposures from valaciclovir hydrochloride monohydrate (e.g., at doses for zoster treatment or CMV prophylaxis), caution is required during concurrent administration with drugs which inhibit active renal tubular secretion.</p><p>Increases in plasma AUCs of aciclovir and of the inactive metabolite of mycophenolate motefil, an immunosuppressant agent used in transplant patients, have been shown when the drugs are co-administered. No changes in peak concentrations or AUCs are observed with coadministration of valaciclovir hydrochloride monohydrate and mycophenolate mofetil in healthy volunteers. There is limited clinical experience with the use of this combination.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p>A limited amount of data on the use of valaciclovir hydrochloride monohydrate and a moderate amount of data on the use of aciclovir in pregnancy is available from pregnancy registries (which have documented the pregnancy outcomes in women exposed to valaciclovir hydrochloride monohydrate or to oral or intravenous aciclovir (the active metabolite of valaciclovir hydrochloride monohydrate); 111 and 1246 outcomes (29 and 756 exposed during the first trimester of pregnancy, respectively) and postmarketing experience indicate no malformative or foeto/neonatal toxicity. Animal studies do not show reproductive toxicity for valaciclovir hydrochloride monohydrate (see section 5.3). Valaciclovir hydrochloride monohydrate should only be used in pregnancy if the potential benefits of treatment outweigh the potential risk.</p><p>Breastfeeding</p><p>Aciclovir, the principle metabolite of valaciclovir hydrochloride monohydrate, is excreted in breast milk. However, at therapeutic doses of valaciclovir hydrochloride monohydrate, no effects on the breastfed newborns/infants are anticipated since the dose ingested by the child is less than 2% of the therapeutic dose of intravenous aciclovir for treatment of neonatal herpes (see Section 5.2). Valaciclovir hydrochloride monohydrate should be used with caution during breast feeding and only when clinically indicated.</p><p>Fertility</p><p>Valaciclovir hydrochloride monohydrate did not affect fertility in rats dosed by the oral route. At high parenteral doses of aciclovir testicular atrophy and aspermatogenesis have been observed in rats and dogs. No human fertility studies were performed with valaciclovir hydrochloride monohydrate, but no changes in sperm count, motility or morphology were reported in 20 patients after 6 months of daily treatment with 400 to 1000 mg aciclovir.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. The clinical status of the patient and the adverse reaction profile of Valaciclovir hydrochloride monohydrate hydrochloride monohydrate should be borne in mind when considering the patient`s ability to drive or operate machinery. Further, a detrimental effect on such activities cannot be predicted from the pharmacology of the active substance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most common adverse reactions (ARs) reported in at least one indication by patients treated with Valaciclovir hydrochloride monohydrate hydrochloride monohydrate in clinical trials were headache &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; More &nbsp; serious &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ARs &nbsp;&nbsp;&nbsp; such &nbsp;&nbsp;&nbsp; as &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thrombotic &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thrombocytopenic purpura/haemolytic uraemic syndrome, acute renal failure and neurological disorders are discussed in greater detail in other sections of the label.</p><p>Undesirable effects are listed below by body system organ class and by frequency.</p><p>The following frequency categories are used for classification of adverse effects:</p><p>Very common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge; 1/10,</p><p>Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;1/100 to &lt; 1/10,</p><p>Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge; 1/1,000 to &lt; 1/100,</p><p>Rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge; 1/10,000 to &lt; 1/1000,</p><p>Very rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt; 1/10,000</p><p>Clinical trial data have been used to assign frequency categories to ARs if, in the trials, there was evidence of an association with valaciclovir hydrochloride monohydrate.</p><p>For ARs identified from postmarketing experience, but not observed in clinical trials, the most conservative value of point estimate (&ldquo;rule of three&rdquo;) has been used to assign the AR frequency category. For ARs identified as associated with valaciclovir hydrochloride monohydrate from post-marketing experience, and observed in clinical trials, study incidence has been used to assign the AR frequency category. The clinical trial safety database is based on 5855 subjects exposed to valaciclovir hydrochloride monohydrate in clinical trials covering multiple indications (treatment of herpes zoster, treatment/suppression of genital herpes &amp; treatment of cold sores).</p><p><u>Clinical Trial Data</u> <u>Nervous system disorders</u></p><p>Very common:&nbsp;&nbsp;&nbsp; Headache</p><p><u>Gastrointestinal disorders</u></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea</p><p>Post Marketing Data Blood and lymphatic system disorders</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Leucopenia, thrombocytopenia</p><p>Leucopenia is mainly reported in immunocompromised patients.</p><p><u>Immune system disorders</u></p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaphylaxis</p><p>Psychiatric and nervous system disorders&nbsp;</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confusion, hallucinations, decreased consciousness, tremor, agitation</p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ataxia, dysarthria, convulsions, encephalopathy, coma, psychotic symptoms. Neurological disorders, sometimes severe, may be linked to encephalopathy and include confusion, agitation convulsions, hallucinations, coma. These events are generally reversible and usually seen in patients with re impairment or with other predisposing factors (see section 4.4). In organ transplant patients receiving high d mg daily) of Valaciclovir hydrochloride monohydrate hydrochloride monohydrate for CMV prophylaxis, neurological reactions occurred more frequently compared with low used for other indications.</p><p><u>Respiratory, thoracic and mediastinal disorders</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Uncommon:Dyspnoea&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Gastrointestinal disorders</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting, diarrhoea.</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal discomfort</p><p><u>Hepato-biliary disorders</u></p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reversible increases in liver function tests (e.g. bilirubin, liver enzymes).</p><p>Skin and subcutaneous tissue disorders</p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rashes including photosensitivity, pruritus.</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urticaria</p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Angioedema</p><p>Renal and urinary disorders</p><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Renal pain</p><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Renal impairment, acute renal failure (especially in elderly patients or in patients with impairment receiving higher than the recommended doses).</p><p>Renal pain may be associated with renal failure.</p><p>Intratubular precipitation of aciclovir crystals in the kidney has also been reported. Adequate fluid intake sho ensured during treatment (see section 4.4).</p><p>Additional information on special populations</p><p>There have been reports of renal insufficiency, microangiopathic haemolytic anaemia and thrombocytopenia (sometimes in combination) in severely immunocompromised adult patients, particularly those with advance disease, receiving high doses (8000 mg daily) of valaciclovir hydrochloride monohydrate for prolonged periods in clinical trials. These fin also been observed in patients not treated with valaciclovir hydrochloride monohydrate who have the same underlying or concurrent cor</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows co monitoring of the benefit/risk balance of the medicinal product follow below mentioned address.<br /><strong><em>&bull; </em>Saudi Arabia<em>:</em></strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:510px"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: <u>npc.drug@sfda.gov.sa</u><br />o Website: <u>www.sfda.gov.sa/npc</u></p></td></tr></tbody></table><p><strong>Other GCC States:</strong></p><p>Please contact the relevant competent authority.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms and Signs</p><p>Acute renal failure and neurological symptoms, including confusion, hallucinations, agitation, decreased consciousness and coma, have been reported in patients receiving overdoses of valaciclovir hydrochloride monohydrate. Nausea and vomiting may also occur. Caution is required to prevent inadvertent overdosing. Many of the reported cases involved renally impaired and elderly patients receiving repeated overdoses, due to lack of appropriate dosage reduction.</p><p>Treatment</p><p>Patients should be observed closely for signs of toxicity. Haemodialysis significantly enhances the removal of aciclovir from the blood and may, therefore, be considered a management option in the event of symptomatic overdose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Antivirals for systemic use</p><p>Pharmacotherapeutic group: Nucleosides and nucleotides excluding reverse transcriptase inhibitors, ATC code: J05AB11</p><p>Mechanism of action</p><p>Valaciclovir hydrochloride monohydrate, an antiviral, is the L-valine ester of aciclovir. Aciclovir is a purine (guanine) nucleoside analogue.</p><p>Valaciclovir hydrochloride monohydrate is rapidly and almost completely converted in man to aciclovir and valine, probably by the enzyme referred to as valaciclovir hydrochloride monohydrate hydrolase.</p><p>Aciclovir is a specific inhibitor of the herpes viruses with in vitro activity against herpes simplex viruses (HSV) type 1 and type 2, varicella zoster virus (VZV), cytomegalovirus (CMV), EpsteinBarr Virus (EBV), and human herpes virus 6 (HHV-6). Aciclovir inhibits herpes virus DNA synthesis once it has been phosphorylated to the active triphosphate form.</p><p>The first stage of phosphorylation requires the activity of a virus-specific enzyme. In the case of HSV, VZV and EBV this enzyme is the viral thymidine kinase (TK), which is only present in virus-infected cells. Selectivity is maintained in CMV with phosphorylation, at least in part, being mediated through the phosphotransferase gene product of UL97. This requirement for activation of aciclovir by a virus-specific enzyme largely explains its selectivity.</p><p>The phosphorylation process is completed (conversion from mono- to triphosphate) by cellular kinases. Aciclovir triphosphate competitively inhibits the virus DNA polymerase and incorporation of this nucleoside analogue results in obligate chain termination, halting virus DNA synthesis and thus blocking virus replication.</p><p>Pharmacodynamic effects</p><p>Resistance to aciclovir is normally due to a thymidine kinase deficient phenotype which results in a virus which is disadvantaged in the natural host. Reduced sensitivity to aciclovir has been described as a result of subtle alterations in either the virus thymidine kinase or DNA polymerase. The virulence of these variants resembles that of the wild-type virus.</p><p>Monitoring of clinical HSV and VZV isolates from patients receiving aciclovir therapy or prophylaxis has revealed that virus with reduced sensitivity to aciclovir is extremely rare in the immunocompetent host and is found infrequently in severely immunocompromised individuals e.g. organ or bone marrow transplant recipients, patients receiving chemotherapy for malignant disease and people infected with the human immunodeficiency virus (HIV).</p><p>Clinical studies</p><p>Varicella Zoster Virus Infection</p><p>Valaciclovir hydrochloride monohydrate hydrochloride monohydrate accelerates the resolution of pain: it reduces the duration of and the proportion of patients with zoster-associated pain, which includes acute and, in patients older than 50 years, also post-herpetic neuralgia. Valaciclovir hydrochloride monohydrate hydrochloride monohydrate reduces the risk of ocular complications of ophthalmic zoster.</p><p>Intravenous therapy generally is considered standard for zoster treatment in immunocompromised patients; however, limited data indicate a clinical benefit of valaciclovir hydrochloride monohydrate in the treatment of VZV infection (herpes zoster) in certain immunocompromised patients, including those with solid organ cancer, HIV, autoimmune diseases, lymphoma, leukaemia and stem cell transplants.</p><p>Herpes Simplex Virus Infection</p><p>Valaciclovir hydrochloride monohydrate for ocular HSV infections should be given according to applicable treatment guidelines.</p><p>Studies of valaciclovir hydrochloride monohydrate treatment and suppression for genital herpes were performed in HIV/HSV coinfected patients with a median CD4 count of &gt; 100cells/mm3. Valaciclovir hydrochloride monohydrate 500 mg twice daily was superior to 1000 mg once daily for suppression of symptomatic recurrences Valaciclovir hydrochloride monohydrate 1000 mg twice daily for treatment of recurrences was comparable to oral aciclovir 200 mg five times daily on herpes episode duration. Valaciclovir hydrochloride monohydrate has not been studied in patients with severe immune deficiency.</p><p>The efficacy of valaciclovir hydrochloride monohydrate for the treatment of other HSV skin infections has been documented. Valaciclovir hydrochloride monohydrate has shown efficacy in the treatment of herpes labialis (cold sores), mucositis due to chemotherapy or radiotherapy, HSV reactivation from facial resurfacing, and herpes gladiatorum. Based on historical aciclovir experience, valaciclovir hydrochloride monohydrate appears to be as effective as aciclovir for the treatment of erythema multiforme, eczema herpeticum and herpetic whitlow.</p><p>Valaciclovir hydrochloride monohydrate has been proven to reduce the risk of transmission of genital herpes in immunocompetent adults when taken as suppressive therapy and combined with safer sex practices. A double blind, placebo controlled study was conducted in 1,484 heterosexual, immunocompetent adult couples discordant for HSV-2 infection. Results showed significant reductions in risk of transmission: 75 % (symptomatic HSV-2 acquisition), 50 % (HSV-2 seroconversion), and 48 % (overall HSV-2 acquisition) for valaciclovir hydrochloride monohydrate compared to placebo. Among subjects participating in a viral shedding sub-study, valaciclovir hydrochloride monohydrate significantly reduced shedding by 73 % compared to placebo (see section 4.4 for additional information on transmission reduction).</p><p>Cytomegalovirus Infection (see section 4.4)</p><p>CMV prophylaxis with valaciclovir hydrochloride monohydrate in subjects receiving solid organ transplantation (kidney, heart) reduces the occurrence of acute graft rejection, opportunistic infections and other herpes virus infections (HSV, VZV). There is no direct comparative study versus valganciclovir to define the optimal therapeutic management of solid organ transplant patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption</p><p>Valaciclovir hydrochloride monohydrate is a prodrug of aciclovir. The bioavailability of aciclovir from valaciclovir hydrochloride monohydrate is about 3.3 to 5.5-fold greater than that historically observed for oral aciclovir. After oral administration valaciclovir hydrochloride monohydrate is well absorbed and rapidly and almost completely converted to aciclovir and valine. This conversion is probably mediated by an enzyme isolated from human liver referred to as valaciclovir hydrochloride monohydrate hydrolase. The bioavailability of aciclovir from 1000 mg valaciclovir hydrochloride monohydrate is 54%, and is not reduced by food. Valaciclovir hydrochloride monohydrate pharmacokinetics is not doseproportional. The rate and extent of absorption decreases with increasing dose, resulting in a less than proportional increase in C<sub>max </sub>over the therapeutic dose range and a reduced bioavailability at doses above 500 mg. Aciclovir pharmacokinetic (PK) parameter estimates following single doses of 250 to 2000 mg valaciclovir hydrochloride monohydrate to healthy subjects with normal renal function are shown below.</p><table border="0" cellspacing="0" cellpadding="0" style="width:631px"><tbody><tr><td colspan="2" style="vertical-align:top"><p>Aciclovir PK Parameter</p></td><td style="vertical-align:top"><p>250 mg (N = 15)</p></td><td style="vertical-align:top"><p>500 mg (N = 15)</p></td><td style="vertical-align:top"><p>1000 mg</p><p>(N = 15)</p></td><td style="vertical-align:top"><p>2000 mg</p><p>(N = 8)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cmax</p></td><td style="vertical-align:top"><p>micrograms/mL</p></td><td style="vertical-align:top"><p>2.20 &plusmn; 0.38</p></td><td style="vertical-align:top"><p>3.37 &plusmn; 0.95</p></td><td style="vertical-align:top"><p>5.20 &plusmn; 1.92</p></td><td style="vertical-align:top"><p>8.30 &plusmn; 1.</p></td></tr><tr><td style="vertical-align:top"><p>Tmax</p></td><td style="vertical-align:top"><p>hours (h)</p></td><td style="vertical-align:top"><p>0.75 (0.75&ndash;</p><p>1.5)</p></td><td style="vertical-align:top"><p>1.0 (0.75&ndash;</p><p>2.5)</p></td><td style="vertical-align:top"><p>2.0 (0.75&ndash;</p><p>3.0)</p></td><td style="vertical-align:top"><p>2.0 (1.5&ndash;</p></td></tr></tbody></table><p>AUC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; h.micrograms/mL 5.50 &plusmn; 0.82 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 11.1 &plusmn; 1.75 &nbsp;&nbsp;&nbsp;&nbsp; 18.9 &plusmn; 4.51 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 29.5 &plusmn; 6.</p><p>C<sub>max</sub> = peak concentration; T = time to peak concentration; AUC = area under the concentrationtime curve. Values for C and AUC denote mean &plusmn; standard deviation. Values for T denote median and range.</p><p>Peak plasma concentrations of unchanged valaciclovir hydrochloride monohydrate are only about 4% of peak aciclovir levels, occur at a median time of 30 to 100 min post-dose, and are at or below the limit of quantification 3 h after dosing. The valaciclovir hydrochloride monohydrate and aciclovir pharmacokinetic profiles are similar after single and repeat dosing. Herpes zoster, herpes simplex and HIV infection do not significantly alter the pharmacokinetics of valaciclovir hydrochloride monohydrate and aciclovir after oral administration of valaciclovir hydrochloride monohydrate compared with healthy adults. In transplant recipients receiving valaciclovir hydrochloride monohydrate 2000 mg 4 times daily, aciclovir peak concentrations are similar to or greater than those in healthy volunteers receiving the same dose. The estimated daily AUCs are appreciably greater.</p><p>Distribution</p><p>Binding of valaciclovir hydrochloride monohydrate to plasma proteins is very low (15%). CSF penetration, determined by CSF/plasma AUC ratio, is independent of renal function and was about 25% for aciclovir and the metabolite 8-OH-ACV, and about 2.5% for the metabolite</p><p>CMMG.</p><p>Biotransformation</p><p>After oral administration, valaciclovir hydrochloride monohydrate is converted to aciclovir and <em>L-</em>valine by first-pass intestinal and/or hepatic metabolism. Aciclovir is converted to a small extent to the metabolites 9(carboxymethoxy) methylguanine (CMMG) by alcohol and aldehyde dehydrogenase and to 8-hydroxy-aciclovir (8-OH-ACV) by aldehyde oxidase. Approximately 88% of the total combined plasma exposure is attributable to aciclovir, 11% to CMMG and 1% to 8-OH-ACV. Neither valaciclovir hydrochloride monohydrate nor aciclovir is metabolized by cytochrome P450 enzymes.</p><p>Elimination</p><p>Valaciclovir hydrochloride monohydrate is eliminated in the urine principally as aciclovir (greater than 80% of the recovered dose) and the aciclovir metabolite CMMG (about 14% of the recovered dose). The metabolite 8-OH-ACV is detected only in small amounts in urine (&lt; 2% of the recovered dose). Less than 1% of the administered dose of valaciclovir hydrochloride monohydrate is recovered in the urine as unchanged drug. In patients with normal renal function the plasma elimination half-life of aciclovir after both single and multiple dosing with valaciclovir hydrochloride monohydrate is approximately 3 h.</p><p>Special Populations</p><p>Renal impairment</p><p>The elimination of aciclovir is correlated to renal function, and exposure to aciclovir will increase with increased renal impairment. In patients with end-stage renal disease, the average elimination half-life of aciclovir after valaciclovir hydrochloride monohydrate administration is approximately 14 hours, compared with about 3 hours for normal renal function (see section 4.2).</p><p>Exposure to aciclovir and its metabolites CMMG and 8-OH-ACV in plasma and cerebrospinal fluid (CSF) was evaluated at steady-state after multiple-dose valaciclovir hydrochloride monohydrate administration in 6 subjects with normal renal function (mean creatinine clearance 111 mL/min, range 91-144 mL/min) receiving 2000 mg every 6 hours and 3 subjects with severe renal impairment (mean CLcr 26 mL/min, range 17-31 mL/min) receiving 1500 mg every 12 hours. In plasma as well as CSF, concentrations of aciclovir, CMMG and 8-OH-ACV were on average 2, 4 and 5-6 times higher, respectively, at severe renal impairment compared with normal renal function.</p><p>Hepatic impairment</p><p>Pharmacokinetic data indicate that hepatic impairment decreases the rate of conversion of valaciclovir hydrochloride monohydrate to aciclovir but not the extent of conversion. Aciclovir half-life is not affected.</p><p>Pregnant women</p><p>A study of the pharmacokinetics of valaciclovir hydrochloride monohydrate and aciclovir during late pregnancy indicates that pregnancy does not affect the pharmacokinetics of valaciclovir hydrochloride monohydrate.</p><p>Transfer into breast milk</p><p>Following oral administration of a 500 mg dose of valaciclovir hydrochloride monohydrate, peak aciclovir concentrations (Cmax) in breast milk ranged from 0.5 to 2.3 times the corresponding maternal aciclovir serum concentrations. The median aciclovir concentration in breast milk was 2.24 micrograms/ml (9.95 micromoles/L). With a maternal valaciclovir hydrochloride monohydrate dosage of 500 mg twice daily, this level would expose a nursing infant to a daily oral aciclovir dosage of about 0.61 mg/kg/day. The elimination half-life of aciclovir from breast milk was similar to that for serum. Unchanged valaciclovir hydrochloride monohydrate was not detected in maternal serum, breast milk, or infant urine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential.</p><p>Valaciclovir hydrochloride monohydrate did not affect fertility in male or female rats dosed by the oral route.</p><p>Valaciclovir hydrochloride monohydrate was not teratogenic in rats or rabbits. Valaciclovir hydrochloride monohydrate is almost completely metabolised to aciclovir. Subcutaneous administration of aciclovir in internationally accepted tests did not produce teratogenic effects in rats or rabbits. In additional studies in rats, foetal abnormalities and maternal toxicity were observed at subcutaneous doses that produced plasma aciclovir levels of 100 micrograms/mL (&gt;10-fold higher than 2000 mg single dose valaciclovir hydrochloride monohydrate in humans with normal renal function).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Valaciclovir Tablets 500mg:</u> </strong></p><p>The other ingredients are: Cellulose Microcrystalline, Crospovidone, Povidone, Purified water,&nbsp;&nbsp;&nbsp; Magnesium Sterate.</p><p>Coating composition: Hypromellose, Titanium dioxide, Polyethylene glycol/Macrogol,&nbsp;Polysorbate 80.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2  Years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C.<strong> </strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp; Valaciclovir Tablets are supplied in Blister pack.</p><p>&nbsp; Valaciclovir Tablets 500 mg- 5 x 10&rsquo;s Alu-PVC Blister Pack</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 Saudi Hetero Lab Co, Ltd. 
Aljameah Street, Malaz quarter, Riyadh 11441 
Saudi Arabia 
Tel: +966 11 477 2215 
Manufacture: Hetero Lab Unit III, Hyderabad, India  

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                NA
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>